| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/10/2009 | US20090304629 Macrocyclic hepatitis c serine protease inhibitors |
| 12/10/2009 | US20090304628 Stabilized pharmaceutical formulations that contain the interferons gamma and alpha in synergistic proportions |
| 12/10/2009 | US20090304627 Smallpox dna vaccine and the antigens therein that elicit an immune response |
| 12/10/2009 | US20090304626 Hepatitis C Virus Inhibitors |
| 12/10/2009 | US20090304625 Modulators of cardiac cell hypertrophy and hyperplasia |
| 12/10/2009 | US20090304599 Protein Nanoparticles and the Use of the Same |
| 12/10/2009 | US20090304597 Use of an Active Biological Substance in Abnormal Cellular and Viral Membrane Physiologies |
| 12/10/2009 | US20090304592 Treatment of metastatic tumors |
| 12/10/2009 | US20090304590 Therapeutic compositions and methods |
| 12/10/2009 | US20090304583 Pathological tissue detection and treatment employing targeted benzoindole optical agents |
| 12/10/2009 | US20090304581 Single wall nanotube constructs and uses therefor |
| 12/10/2009 | US20090304580 Anti-Pancreatic Cancer Antibodies |
| 12/10/2009 | US20090304577 Peptides for Treatment and Diagnosis of Autoimmune Disease |
| 12/10/2009 | US20090304575 In vitro method for identifying compounds for cancer therapy |
| 12/10/2009 | CA2727085A1 Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling |
| 12/10/2009 | CA2727026A1 Use of pegylated type iii interferons for the treatment of hepatitis c |
| 12/10/2009 | CA2727008A1 Use of a dead-box rna helicase for inducing cytokine production |
| 12/10/2009 | CA2726985A1 Small molecule inhibitors for the treatment or prevention of dengue virus infection |
| 12/10/2009 | CA2726949A1 Stimuli-responsive hydrogel |
| 12/10/2009 | CA2726942A1 Fviii muteins for treatment of von willebrand disease |
| 12/10/2009 | CA2726917A1 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| 12/10/2009 | CA2726913A1 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| 12/10/2009 | CA2726903A1 Long-acting glp-1 derivatives, and methods of treating cardiac dysfunction |
| 12/10/2009 | CA2726804A1 Xbp1, cd138, and cs1 peptides |
| 12/10/2009 | CA2726763A1 Controlled release copolymer formulation with improved release kinetics |
| 12/10/2009 | CA2726641A1 Nasal formulations of insulin |
| 12/10/2009 | CA2726603A1 Dosing regimen |
| 12/10/2009 | CA2726589A1 Fgf21 mutants and uses thereof |
| 12/10/2009 | CA2726285A1 Anxiolytic composition containing alphas1-casein-derived peptides |
| 12/10/2009 | CA2726193A1 Methods of treating inflammatory intestinal disease and managing symptoms thereof |
| 12/10/2009 | CA2725628A1 Analgesic effects of peptide toxin apetx2 |
| 12/09/2009 | EP2130920A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 12/09/2009 | EP2130919A1 IL-21 antagonists |
| 12/09/2009 | EP2130915A1 Cell capable of expressing lacritin at high level |
| 12/09/2009 | EP2130555A1 Stimuli-responsive hydrogel |
| 12/09/2009 | EP2130554A1 Novel albumin-free factor VIII formulations |
| 12/09/2009 | EP2130551A1 Improved purification of collagenases from clostridium histolyticum liquid culture |
| 12/09/2009 | EP2130550A1 Use of a dead-box RNA helicase to induce the production of cytokines |
| 12/09/2009 | EP2130549A1 Solid fibrinogen preparation |
| 12/09/2009 | EP2130548A2 Growth Hormone Releasing Peptides |
| 12/09/2009 | EP2130547A1 IL-25 for use in the treatment of inflammatory diseases |
| 12/09/2009 | EP2130546A1 Prophylactic agent for heart failure |
| 12/09/2009 | EP2130545A2 Solution and tincture |
| 12/09/2009 | EP2130534A1 Use of ritonavir for improving the pharmacokinetics of drugs metabolized by cytochrome P450 |
| 12/09/2009 | EP2130532A1 Method for treating conditions associated with the accumulation of excess extracellular matrix |
| 12/09/2009 | EP2129687A2 Novel glp-1 fusion peptides, their production and use |
| 12/09/2009 | EP2129686A1 Methods for industrial scale production of therapeutic complement factor h preparations from human plasma |
| 12/09/2009 | EP2129683A2 Methods and compositions for the treatment of heart failure and other disorders |
| 12/09/2009 | EP2129388A2 Rna targeting compounds and methods for making and using same |
| 12/09/2009 | EP2129370A1 Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue |
| 12/09/2009 | EP2129364A2 Process for manufacturing ophthalmic oil-in-water emulsions |
| 12/09/2009 | EP2129318A2 Flowable carrier compositions for orthopedic implants and methods of use |
| 12/09/2009 | EP1706141B1 Methods of using botulinum toxin for the treatment of hypervolemic lip deformity (lip ectropion) |
| 12/09/2009 | EP1689425B1 Pharmaceutical formulations for the sustained release of one or more active principles and therapeutic applications thereof |
| 12/09/2009 | EP1648493B1 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| 12/09/2009 | EP1558729B1 Rapidly degraded reporter fusion proteins |
| 12/09/2009 | EP1472282B1 Use of calmodulin to promote bone regeneration |
| 12/09/2009 | EP1458754B1 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control |
| 12/09/2009 | EP1444194B1 N-methyl-homocystines, use thereof and method for the production thereof |
| 12/09/2009 | EP1443933B1 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
| 12/09/2009 | EP1129110B1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 12/09/2009 | EP1020179B1 Peptide derivatives or pharmaceutically acceptable salts thereof, method for producing the same, use of said derivatives and pharmaceutical composition |
| 12/09/2009 | CN201356817Y Coptis-coated insulin granule |
| 12/09/2009 | CN101600791A Matrix and method for isolation of hepatic progenitor cells |
| 12/09/2009 | CN101600735A Truncated PTH peptides with a cyclic conformation |
| 12/09/2009 | CN101600456A Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| 12/09/2009 | CN101600452A Pharmaceutical composition containing arazyme for the prevention of liver dysfunction |
| 12/09/2009 | CN101600451A Compositions and methods for treating pathologic angiogenesis and vascular permeability |
| 12/09/2009 | CN101600450A Treatment of demyelinating disorders |
| 12/09/2009 | CN101600449A WNT antagonists and their use in the diagnosis and treatment of WNT-mediated disorders |
| 12/09/2009 | CN101600448A Glycerol linked pegylated sugars and glycopeptides |
| 12/09/2009 | CN101600447A Modifications of cupredoxin derived peptides and methods of use thereof |
| 12/09/2009 | CN101600414A Cosmetic use of chitinase-type proteins<0} |
| 12/09/2009 | CN101597337A Conjugate of hydroxyalkyl starch and an active agent |
| 12/09/2009 | CN101597335A Recombined protein specially combined with fiber protein and application thereof |
| 12/09/2009 | CN101597326A Kahalalide F and related compounds |
| 12/09/2009 | CN101597324A Decapeptide inhibiting angiogenesis and use thereof |
| 12/09/2009 | CN101597322A 17 analogs of Tyr-Ile-Gly-Ser-Arg as well as synthetic method and application thereof in medicine |
| 12/09/2009 | CN101597321A LHRH antagonist with long-acting low-histamine release side effect |
| 12/09/2009 | CN101597291A 2-aminoacyl tryptophyl-Beta-tetrahydric carboline-3-carboxylic acid carbobenzoxy as well as preparation method and application thereof |
| 12/09/2009 | CN101597290A Beta-carboline-3-formyl tryptophyl amine acid carbamate as well as preparation method and application thereof |
| 12/09/2009 | CN101597289A 2-tryptophanyl-Beta-tetrahydric carboline-3-formyol amino-acid benzyl ester and preparation method and application thereof |
| 12/09/2009 | CN101597288A 2-aminoacyl-Beta-3-formyol tryptophan benzyl ester and preparation method and application thereof |
| 12/09/2009 | CN101596320A Medicament for treating tumor and application thereof |
| 12/09/2009 | CN101596311A Stable kallikrein-1 injection |
| 12/09/2009 | CN101596310A Artificial substrate membrane emulsifying paste for wound surface restoration |
| 12/09/2009 | CN101596309A Pharmaceutical composition for preventing and treating livestock and poultry viral disease and effervescing agent prepared by same |
| 12/09/2009 | CN101596308A ITGB4BP and derivates thereof used for preventing and/or treating hypertrophic scar and fibrosis lesion |
| 12/09/2009 | CN101596307A Application of recombinant FN heparin binding domain polypeptide on preparing medicament resisting invasion and metastasis of malignant tumor |
| 12/09/2009 | CN101596306A Pharmaceutical formulations for sustained drug delivery |
| 12/09/2009 | CN100567495C Methods for large scale production of recombinant DNA-derived tPA or K2S molecules |
| 12/09/2009 | CN100567488C Enhancement of virus-mediated DNA transfer |
| 12/09/2009 | CN100567487C Coagulation factor VII derivatives |
| 12/09/2009 | CN100567483C FAD4, FAD5, FAD5-2 and FAD6 fatty acid desaturase enzyme family members and uses thereof |
| 12/09/2009 | CN100567325C VEGF receptor fusion protein and its use in preparation of medicament for treating eye disease |
| 12/09/2009 | CN100567322C Polypeptide for inhibiting growth differentiation factor activity and cell expressing the same |
| 12/09/2009 | CN100566757C Biological degradable polymer-solid liposome sustained-release storing system and preparation method thereof |
| 12/09/2009 | CN100566756C Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons |
| 12/09/2009 | CN100566753C A hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
| 12/09/2009 | CN100566749C Particle medicinal granules for treating pharyngitis and method of producing the same |